लोड हो रहा है...
Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/HCV Patients Receiving Pegylated-Interferon and Ribavirin
INTRODUCTION: Pegylated-interferon (PEG-IFN) and ribavirin (RBV), current standard treatment for hepatitis C virus (HCV) infection, is frequently associated with neutropenia and anemia, leading to high treatment discontinuation rates in HIV/HCV coinfected patients. Our objective was to compare the e...
में बचाया:
मुख्य लेखकों: | , , , , , , , , , , , , , , , |
---|---|
स्वरूप: | Artigo |
भाषा: | Inglês |
प्रकाशित: |
2011
|
विषय: | |
ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3386143/ https://ncbi.nlm.nih.gov/pubmed/21876446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3182324af9 |
टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|